It is well known that Michaelis-Menten kinetics is suitable for the response function in chemical reaction, when the reaction rate does not increase indefinitely when an excess of resource is available. However, the existing models for insulin therapies assume that the response function of insulin clearance is proportional to the insulin concentration. In this paper, we propose a new model for insulin therapy for both type 1 and type 2 diabetes mellitus, in which the insulin degradation rate assumes Michaelis-Menten kinetics. Our analysis shows that it is possible to mimic pancreatic insulin secretion by exogenous insulin infusions, and our numerical simulations provide clinical strategies for insulin-administration practices.
Modelling the glucose-insulin feedback system
Diabetes mellitus is a disorder of the glucose-insulin endocrine metabolic regulatory system. It is caused by the fact that either the pancreas does not produce enough insulin to consume the glucose, or the insulin is not used efficiently by the cells to metabolize the glucose. The diabetic population accounts for approximately 7% of the whole population in US, and the health expense is huge (≈132 billion US dollars annually, ADA, http://www.diabetes.org). Many researchers have been attracted to the study of glucose-insulin regulatory system with an ultimate goal of providing more efficient, effective, and economic insulin therapies for diabetics (e.g., [1, [6] [7] [8] [9] 12, 13, 15, 17, 18, 21, 29, 30, 37, 39, 40, 43, 48, 49] ).
In the last two decades, several mathematical models have been proposed and studied with the aim of understanding the system better, investigating possible pathways to diabetes mellitus, or providing more reasonable insulin administration practices ( [4, 5, 10, 13, 14, 25, 27, 28, 33, 35, 36, 41, 42, 44, 48, 49] and references therein.) For example, recently, according to the mass conservation law, Li et al. [28] proposed a two-delay model for understanding the self-constrained regulatory mechanism of the system better. With the explicit delays, the model is more accurate for depicting glucose-insulin endocrine metabolic dynamics. The model is given as follows.
G = G in − f 2 (G(t)) − f 3 (G(t))f 4 (I (t)) + f 5 (I (t − τ
where G in stands for the constant glucose exogenous infusion (enteral nutrition or constant infusion), f 2 (G) stands for the insulin-independent glucose consumptions, f 3 (G)f 4 (I ) stands for the insulin-dependent glucose utilizations, f 5 (I ) stands for the hepatic glucose production with the delayed effect (τ 2 ), f 1 (G) stands for the insulin secretion from the pancreas because of the stimulations of elevated glucose concentration, τ 1 reflects the time lag of the stimulation, and d i is the insulin degradation rate. However, the existing insulin therapy models are inadequate [13, 14, 48, 49] , either only type 1 diabetes insulin administration is considered [49] , or some factor in the system is oversimplified. For example, the insulin degradation rate is assumed to be proportional to insulin concentration [28, 45, 48] . It is well known that in a chemical reaction, the change rate typically increases with the increasing resource, but does not increase indefinitely when an excess of resource is available. In the glucose-insulin metabolic system, the number of insulin receptors of each cell changes vice versa with the circulating insulin concentration level. An increased insulin circulating level reduces the number of insulin receptors per cell, and the decreased circulating level of insulin triggers the number of receptors to increase. The number of receptors is increased during starvation and decreased in obesity and acromegaly. But, the receptor affinity is decreased by excess glucocorticoids. The affinity of the receptor for the second insulin molecule is significantly lower than for the first bound molecule. This may explain the negative cooperative interactions observed during high insulin concentrations. That is, as the concentration of insulin increases and more receptors become occupied, the affinity of the receptors for insulin decreases. Conversely, at low insulin concentrations, positive cooperation has been recorded. In other words, the binding of insulin to its receptor at low insulin concentrations seems to enhance the binding further [46] . Thus, it is more realistic to assume that the insulin degradation rate obeys Michaelis-Menten kinetics given by
where d 1 is the maximum insulin clearance rate and d 2 is the half-saturation value. The idea of this paper is to propose an insulin therapy model suitable for both type 1 and type 2 diabetes mellitus, and to incorporate the Michaelis-Menten response function as the insulin degradation rate. The model is given by
with initial conditions I (0) > 0, G(0) > 0, and
, where α > 0 and β ∈ [0, 1]. For type 1 diabetics, β = 0, as no insulin would be secreted from the pancreas. For type 2 diabetics, 0 < β ≤ 1 observing that some, although not enough, amount of insulin can be secreted from pancreas [31] . The positive parameter α in Equation (2) describes insulin-dosage adjustment, which could improve the control of glucose concentration of the subjects. Furthermore, it has been revealed that the oscillatory insulin delivery with an ultradian periodicity is more efficient in reducing blood glucose levels than constant insulin administration [42] . In model 2, we assume that insulin injection I in and glucose intake G in are positive periodic functions with a common period, ω > 0. The common period is determined by the timing of meal ingestion and by subcutaneous insulin administration on a period sufficiently large to imagine both the glucose insulin mass administered eventually diffused in the IV compartment at the end of the period. Since Equation (2) models the exogenous insulin administration for both types of diabetes, the oscillations of insulin concentration and glucose concentration are resulted from the forced terms with common period ω; and the delay τ 1 for insulin production is more significant than the delayed effect of hepatic glucose production (τ 2 in model (1)). So, for simplicity, this delayed effect is neglected in Equation (2) for qualitative behaviour. Throughout the paper, we assume the following conditions:
Assumptions (H1)-(H6) are quite natural. Note that if f 2 takes the form in Equation (5) 
Thus, it is easy to see that conditions (H1)-(H5) cover the model functions in Equations (5)-(8) used in [25, 27, 41, 44, 48] for numerical simulations. Assumption (H6) indicates that the maximum insulin clearance rate is larger than the addition of the maximum insulin infusion and production rates. Physiologically, the shapes of the functions are important instead of their forms [22] (Figure 1 ). The shapes of the functions are detailed in earlier studies [22, 25, 28, 41] . 
Mathematical analysis
In this section, the positivity and boundedness of solutions of Equation (2) will be examined. We will also state results for the existence of a positive solution of Equation (2) and its stability. Detailed proofs of the existence and stability will be carried out in Appendices. Throughout this section, we assume conditions (H1-H6) are true. LEMMA 2.1 All solutions of Equation (2) exist for t > 0, and they are positive and bounded from above.
Proof The solution for Equation (2) with the described initial conditions exist and is unique [24] . Let (G(t), I (t)) be a solution of Equation (2) with initial conditions
which is a contradiction. Therefore, G(t) > 0 for t > 0. By the same argument, I (t) is positive for all t > 0.
Now we show the boundedness of (G(t), I (t)).
From Equation (2), we have
where m 4 > 0 is the lower bound of f 4 (I (t)) on [0,∞]. Therefore,
The boundedness also implies that G(t) exists for all t > 0. Now considering the second equation of (2), we have
In fact, we can easily prove, by Lemma 2.2,
Thus, I (t) is bounded and also implies that I (t) exists for all t > 0.
Let (I (t), G(t)) be a solution of Equation (2). We definē
Lemma 2.1 implies thatḠ, G,Ī , I are all finite. The well-known fluctuation lemma is stated below without proof. Its proof can be found in, e.g., Hirsch et al. [20] . (2) is uniformly persistent, i.e. solutions of Equation (2) are eventually uniformly bounded from above and away from zero.
LEMMA 2.3 Equation
Proof We only need to show that G > 0 and I > 0. By the fluctuation lemma, there exist a sequence {t k } ↑ ∞, such that
Thus, the second equation of (2) gives, for all k,
and as f 4 is increasing and f 5 is non-negative, we have
,
which is a contradiction. Thus, G > 0. It remains to show that I > 0. Again by the fluctuation lemma, there exist a sequence {s k } ↑ ∞ such that
and as f 1 is non-negative, we have
Letting k → ∞, we have
If I = 0, we have
which is a contradiction. This completes the proof of the lemma.
To have a positive periodic solution, the left side of the second equation of (2) must change sign. If the rates of insulin injection and insulin production, αI in (t) + βf 1 (G(t − τ 1 )), are too large, then the rate of change of insulin, dI/dt, may be always positive and therefore Equation (2) does not have a periodic solution. In the following existence theorem, we assume that αI in (t) + βf 1 (x) is small enough so that inequality Equation (16) in Appendix 1 holds.
has a positive periodic solution (G*, I*).
Finally we state the stability result in the following theorem. (2) is locally asymptotically stable if conditions (18) and (19) in Appendix 2 are satisfied.
THEOREM 2.5 The periodic solution (G*, I*) of Equation
Precise mathematical expressions of conditions (18) and (19) are given in Appendix 2. Based on the expressions of (18) and (19) , and inequality Equation (3), if the maximal insulin clearance rate d 1 is large, the delay τ 1 is small, then, as a lower bound of f 0 (t)
), σ 0 can be large so thatĈ > 0. Similarly, if f 2 and f 3 f 4 are large, that is, the insulin utilizations are more effective, thenD > 0. These observations are in agreement with the study of Li and Kuang [25] .
The proof of Theorem 2.4 is based on the Krasnoselskii fixed point theorem (Lemma A.1), and see Appendix 1 for details. The proof of Theorem 2.5 is based on a standard construction of a Lyapunov functional and will be carried out in Appendix 2.
Applications in clinical insulin therapies
In this section, we will discuss an application of model (2) in clinical insulin therapies. The simulations demonstrate that the new model (2) is suitable for the study of the effectiveness of clinical insulin therapies. In particular, we will see that model (2) is more realistic. In a normal subject, the liver releases glucose into the blood. This helps the body to maintain cells functioning all 24 h. The pancreas responds by releasing a small but steady amount of insulin (basal) into the bloodstream day and night in a pulsatile manner. After meals, a large amount of insulin (bolus) is released enough to uptake the glucose produced when food is digested. The goal of intensive insulin therapy is to mimic the natural pattern of insulin release from the pancreas so that plasma glucose levels can be kept close to normal.
Currently, various insulin analogues are available for subcutaneous injection, for example, rapid-acting insulin analogues (Lispro and Aspart), short-acting insulin analogues (buffered regular insulin), intermediate-acting insulin analogues (Lente, NHP), and long-acting insulin analogues (Glargine and Ultralente). Table 1 (adapted from [11] ) lists the time needed for the onset, peak, and duration of several types of insulin.
Our simulations are carried out with the same functions used in previous researches ( [5, 25, 28, 41, 44] ). These functions, f i ; i = 1, 2, 3, 4, 5, take the following forms with experimentally determined parameters given in Table 2 [41, 44] . Model (2) utilizes the functions f 1 to f 5 in Equations (5)- (8) and the parameter values in Table 2 from [41, 44] , which are based on experimental data. These experimental data were taken from normal subjects. With proper insulin treatments, patients can maintain plasma glucose within a normal range, although hypoglycaemia and hyperglycaemia can arise. Therefore, these functions and parameters can be used in the insulin Table 2 . Parameters of the functions in Equations (5)- (8).
Parameters Units Values
therapy model (2) for diabetic patients.
The units of G and I in the functions (5)- (8) are in milligrams and respectively. They are converted to mg dl −1 and μU ml −1 when plotting the figures. Now, we consider model (2) with τ 1 = 5 min, α = 1, β = 0.3, d 1 = 150, and d 2 = 2300.
G(t))f 4 (I (t)) + f 5 (I (t))
If there is no insulin injection, or I in (t) = 0, the profiles of glucose and insulin of Equation (9) is shown in Figure 2 . We see that the blood glucose level is always above 120, which is considered (2) without insulin therapy. to be abnormal blood glucose level. Therefore, insulin injections are needed to bring the blood glucose level down to normal.
As an example, to demonstrate how model (2) can be used in clinical insulin therapy strategies, we select the combination of Lispro and Glargine to mimic the bolus insulin and basal insulin infusion. For simplicity, we assume that G in (t) and I in (t) are periodic piecewise linear functions defined by the following two expressions over a period of ω = 240 min. That is, we assume that both the meal digestion and the diffusion of subcutaneous insulin injection are linearly dependent on time. They can be extended to a periodic continuous function on [0, ∞). Namely, a subject consumes meal and is given insulin injection every 4 h. The maximum glucose intake was at 5 mg/min attained at 15 min mark. The whole duration of the glucose intake lasted for 35 min. Equation (10) is the glucose intake rate, G in (Figure 3) .
We consider the combination of Glargine and Lispro insulins. The piecewise functions of I in Lispro in Equation (11) and I in Glargine in Equation (12) mimic the insulin infusion rate if a patient takes Lispro or Glargine. The rapid-acting insulin mimics the bolus ultradian insulin secretion stimulated by the elevated glucose concentration level, while the long-acting insulin mimics the basal pulsatile insulin secretion. It is clear that the common period for G in (t) and I in (t) is ω = 240 min. 
and With τ 1 = 5 min and α = 1, β = 0.3, the simulation in Figure 4 (a) and (b) demonstrate the glucose and insulin concentration profiles of four injections a day of bolus insulin Lispro and one injection a day of basal insulin Glargine. The insulin injection rate is the combination of I in Glargine (t) and I in Lispro (t). Therefore, I in in Equation (9) takes the following expression.
It is easy to see that I in in Equation (13) <10 and f 1 (x) ≤ 210 for x ∈ [0, ∞). Thus, the condition (H6),
, is satisfied for model (9) .
The glucose level shown in Figure 4 (c) for model (9) is between 70 and 100 mg dl −1 . It is seen that the profiles are close to the profiles of a normal subject. We should also point out that blood glucose levels could be close to 160 mg dl −1 after meals [32] .
Discussions
To optimize the strategies of insulin adminstration, we choose the combination of insulin Glargine and Lispro as basal and bolus insulin, respectively, because clinical trials have shown that insulin Glargine plus insulin Lispro can improve glycaemic control of type 1 diabetes [2] . In their study, the combination of insulin Glargine with insulin Lispro was compared with NPH insulin plus unmodified human insulin. It is reported that there was as much as 44% reduction of monthly rate of nocturnal hypoglycaemia with Glargine plus Lispro. These improvements in blood glucose control were obtained without any increase in episodes of hypoglycaemia. In fact, in another clinical trial by Murphy et al. [34] , it has been documented that combination therapy with insulin Glargine plus insulin Lispro reduced the incidence of nocturnal hypoglycemia and was at least as effective as R/NPH insulin therapy in maintaining glycaemic control. Currently, an insulin pump is the most advanced method of insulin administration for type 1 diabetes [26] . With careful integration of the existing models for glucose absorption from the gut and/or subcutaneous insulin absorption and the regulation of glucose-insulin, an artificial pancreas can be created and put forward in clinical applications. The model proposed in this paper when integrated with the models proposed in earlier studies [25, 26] , can form a solid foundation for an artificial pancreas.
Model (2) does not take into account individual patient factors, such as age, treatment schedule, and exercise. Patient factors, including individual variations in insulin absorption, levels of exercise, local massage, and especially, local subcutaneous blood flow that can influence the effectiveness of an insulin regimen [16] . The time taken to absorb one-half of an injected dose of insulin may vary by 25-50% among individual patients [19] . Thus, it is important to implement individualized therapies, which are flexible to fit the needs of the patient. Model (2) can be adjusted to reflect the patient factors by incorporating a time delay in I in .
In model (2), we neglect the delayed effect of hepatic glucose production in f 5 . In fact, the delayed effect on the dynamics of glucose and insulin for normal subjects under continuous and constant glucose infusion can be significant [25, 28] . We will further investigate the delayed effect in a future research.
Experimental results by Rassam et al. [38] demonstrated that the injection of Lispro insulin 15-30 min before meal can optimally reduce postprandia hyperglycaemia. In our simulation, we assume that lispro insulin is injected 15 min before meal. Other regular insulins are recommended to be injected 30 or 45 min before meal. In practice, patients often inject insulin closer to mealtime, causing a higher postprandial serum glucose level and an increased potential for hypoglycaemia in the postabsorptive period. Thus, Lispro insulin results in more satisfactory postprandial glucose control.
In summary, we propose a new insulin therapy model using Michaelis-Menten kinetics. We are focusing on studying the dynamics of the model, and will continue the research and validate the model to fit actual data of the subjects.
Appendix 1. Proof of Theorem 2.4
In this section, we will give a proof of Theorem 2.4. A related result can be found in [47] . Before we state the Krasnoselskii fixed point theorem, let us recall some concepts and conclusions of an operator in a cone in [23] . Let X be a Banach space and K be a closed, non-empty subset of X. K is said to be a cone if (1) αu + β ∈ K for all u, v ∈ K and all α, β > 0 and (2) u, −u ∈ K, imply u = 0. Assume is a bounded open subset in X with the boundary ∂ , and let T : K ∩ → K be completely continuous, such that T x = x for x ∈ ∂ ∩ K.
LEMMA .1 Krasnoselskii's Fixed Point Theorem [23] . Let X be a Banach space and let K ∈ X be a cone in X. Assume that 1 , 2 are open subsets of X with 0 ∈ 1 , 1 ⊂ 2 and let
be a completely continuous operator, such that either
First, since f 4 is bounded below and above, we can assume there exist two positive numbers m 4 and M 4 , such that 
Now, consider the Banach space
where A, B, C, D are defined by the following expressions: 
and
where
Note that
In order to use the above fixed point theorem we need the following lemma. 
It is easy to see that
Thus T (K ∩ ( 2 \ 1 )) ⊂ K and it is easy to show that T is compact and continuous.
LEMMA .3 If (u, v) is a fixed point of T in K ∩ ( 2 \ 1 ), then (u, v) is a positive periodic solution of (2).
Proof 
(v(t)) T 1 (u, v)(t) = (U u (t, t + ω) − U u (t, t)(G in (t) + f 5 (v(t)))
− f 2 (u(t)) u(t) + f 3 (u(t)) u(t) f 4 (v(t)) T 1 (u, v)(t) = f 2 (u(t)) u(t) + f 3 (u(t)) u(t) f 4 (v(t)) u(t) + [G in (t) + f 5 (v(t))] = G in (t) + f 5 (v(t)) − f 2 (u(t)) − f 3 (
u(t))f 4 (v(t)).
In the same way, we can show that
.
Thus, (u, v) is a non-negative ω-periodic solution of (2), which is also positive.
We are now in a position to prove the existence of periodic solution of (2). Then for (u, v) ∈ ∂ r 1 , we have Then, we calculate the derivative of V 1 (t) along the solution of Equation (2). 
